Испанияда іш қуысына жіті енгізілетін химиотерапия HIPEC-тің: Сіз үшін топ-3 клиниканың таңдауын алыңыз

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a concentrated, heated chemotherapy treatment delivered directly into the abdominal cavity during surgery. It targets microscopic cancer cells remaining after a surgeon removes all visible tumors, significantly improving survival rates for advanced abdominal cancers like colorectal and ovarian malignancies.

• Two-step process: Surgeons first perform cytoreductive surgery to remove all visible tumors.
• Heated bath: Chemotherapy heated to 42°C (108°F) circulates for 30 to 90 minutes.
• Enhanced penetration: Heat expands blood vessels, allowing drugs to penetrate tissues more effectively.
• Reduced toxicity: Direct abdominal delivery limits systemic side effects common with intravenous chemotherapy.

Bookimed Expert Insight: Spain offers unique access to pioneers like Dr. Lana Bijelic at Centro Médico Teknon. She trained under Dr. Paul Sugarbaker, the father of the HIPEC procedure. Spanish centers often combine HIPEC with PIPAC (pressurized aerosol chemotherapy), providing more options for patients who may not tolerate traditional major surgery.

Patient Consensus: While patients report this procedure can be physically brutal with intense nausea, many view it as a life-extending standard for stage 4 cancer. Success stories include survivors reaching the 9-year mark after treatment.

HIPEC success in Spain shows a median overall survival reaching 47 months in high-volume centers. Specialized institutions achieve complete cytoreduction in over 90% of cases. Outcomes depend on the Peritoneal Cancer Index, with best results observed when scores remain low, typically under 7.

• Survival rates: Median disease-free survival is approximately 16 months in specialized Spanish oncology centers.
• Success by type: Colorectal cancer patients often achieve median survival between 42 and 46 months.
• Surgical efficacy: Surgeons successfully remove all visible tumors in 90% of selected clinical cases.
• Safety metrics: Mortality rates for this complex procedure stay low, ranging between 2% and 3.4%.

Bookimed Expert Insight: Success in Spain is linked to doctors trained directly by pioneers like Dr. Paul Sugarbaker. Dr. Lana Bijelic at Centro Médico Teknon has performed over 1,300 complex cancer surgeries. This high volume directly correlates with the 90% complete cytoreduction rates seen in top Spanish hospitals.

Patient Consensus: Patients emphasize that success is highly individual and depends more on fitness than statistics. While recurrence is common, around 20% of patients achieve long-term survival lasting up to 9 years.

Hyperthermic intraperitoneal chemotherapy treats advanced cancers that have spread to the abdominal lining, specifically peritoneal carcinomatosis. This intensive therapy targets malignancies including ovarian, colorectal, gastric, and appendix cancers, alongside peritoneal mesothelioma and pseudomyxoma peritonei, by delivering heated drugs directly into the abdominal cavity after surgical tumor removal.

• Gastrointestinal cancers: Effectively targets stage 4 colon, rectal, and advanced stomach (gastric) cancers.
• Gynecologic malignancies: Primarily treats advanced or recurrent ovarian cancer to reduce recurrence risks.
• Rare pathologies: Specialized for appendiceal cancer, primary peritoneal cancer, and asbestos-linked peritoneal mesothelioma.
• Strict eligibility: Limited to patients whose cancer remains confined within the peritoneal cavity.

Bookimed Expert Insight: Spanish oncology centers often provide PIPAC alongside traditional HIPEC, offering a less invasive aerosolized alternative for patients with high-volume ascites. Dr. Alfonso García Fadrique at Hospital Vithas Valencia Turia leads specialized R&D into HIPEC quality standards, which is a critical differentiator when choosing a center for such complex 12-hour surgeries.

Patient Consensus: Patients often view this procedure as a decisive first-line attack rather than a last resort. Many emphasize that while the 2-month recovery is demanding, the potential for remaining disease-free for several years makes the intensive surgery worthwhile.

Top hospitals for HIPEC in Spain include Centro Médico Teknon in Barcelona and Hospital Ruber Internacional in Madrid. These JCI-accredited facilities specialize in cytoreductive surgery combined with heated chemotherapy. They feature surgeons trained by global pioneers to treat peritoneal carcinomatosis, pseudomyxoma peritonei, and advanced abdominal cancers.

• Specialized expertise: Surgeons like Dr. Lana Bijelic trained under HIPEC pioneer Prof. Paul Sugarbaker.
• Advanced technology: Facilities offer robotic Da Vinci Xi systems and pressurized aerosol chemotherapy (PIPAC).
• Clinical trials: Quironsalud Madrid provides access to novel oncology trials for eligible cancer patients.
• High-volume centers: Premier Spanish institutes perform over 170 complex peritoneal surgeries every year.

Bookimed Expert Insight: Data shows a significant experience gap in peritoneal oncology across Europe. At Centro Médico Teknon, Dr. Lana Bijelic has performed over 1,300 complex cancer surgeries. Choosing a surgeon with this specific volume is critical because HIPEC success depends heavily on the thoroughness of the initial debulking surgery.

Patient Consensus: Patients emphasize requesting a Peritoneal Carcinomatosis Index (PCI) score before surgery. They suggest preparing for a 2-week hospital stay and rigorous post-operative monitoring for bowel function recovery.